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Abstract
Objective: To study the interaction between salicylate and class 1 antiarrhythmic agents. Methods: The effects of salicylate
on class 1 antiarrhythmic agent-induced tonic and phasic block of the Na current (INa) of ventricular myocytes and the
upstroke velocity of the action potential (Vmax) of papillary muscles were examined by both the patch clamp technique and
conventional microelectrode techniques. Results : Salicylate enhanced quinidine-induced tonic and phasic block of INa at a
holding potential of 3100 mV but not at a holding potential of 3140 mV; this enhancement was accompanied by a shift of
the hr curve in the presence of quinidine in a further hyperpolarized direction, although salicylate alone did not affect INa.
Salicylate enhanced the tonic and phasic block of Vmax induced by quinidine, aprindine and disopyramide but had little effect
on that induced by procainamide or mexiletine; the enhancing effects were related to the liposolubility of the drugs.
Conclusions: Salicylate enhanced tonic and phasic block of Na channels induced by class 1 highly liposoluble
antiarrhythmic agents. Based on the modulated receptor hypothesis, it is probable that this enhancement was mediated by an
increase in the affinity of Na channel blockers with high lipid solubility to the inactivated state channels. ß 1999 Elsevier
Science B.V. All rights reserved.
Keywords: Salicylate; Na channel; Papillary muscle; Ventricular myocyte; Class 1 antiarrhythmic agent; Modulated receptor theory;
Liposolubility
1. Introduction
Platelet aggregation plays an important role in the
pathogenesis of atherosclerotic complications such as
occlusion of coronary arteries leading coronary heart
disease. For this reason many studies have investi-
gated the drugs that inhibit platelet aggregation.
Acetylsalicylate acid suppresses platelet aggregation
by inhibiting the cyclo-oxygenase enzyme and has
been the most widely studied antiplatelet drug. Sev-
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eral studies have provided convincing evidence that
acetylsalicylate reduces the risk of a second myocar-
dial infarction and the incidence of vascular death in
patients with acute myocardial infarction [1] ; more-
over, it was reported that this drug reduced the risk
of non-fatal myocardial infarction in patients who
had previously su¡ered a TIA or minor stroke [2].
On the other hand, class 1 antiarrhythmic agents are
not often used to treat the ventricular arrhythmias
developing after myocardial infarction, because po-
tent class 1 antiarrhythmic agents have rather dan-
gerous side e¡ects on the normal impulse conduc-
tion, re£ected as a QRS widening, and increase the
probability of converting a single extra beat into ter-
minal ventricular ¢brillation [3,4]. In clinical practice
it is likely that class 1 antiarrhythmic agents will be
administered to patients under treatment with acetyl-
salicylate, to treat or prevent ventricular arrhyth-
mias. However, at present there are no experimental
or clinical data regarding the combined e¡ects of
salicylate and class 1 antiarrhythmic agents on the
heart. It has been reported that both acetylsalicylate
and sodium salicylate prevent arrhythmia during ex-
perimentally induced coronary occlusion in dogs and
rats [5,6], which may be due to the electrophysiolog-
ical e¡ects of salicylate on membrane currents [7]. In
fact, salicylate decreased potassium conductance and
prolonged the inactivation of sodium currents in
squid axons [7], it prolonged the refractory period
in the cat heart [8], and prolonged the duration of
the action potential in sheep Purkinje ¢bers due to a
shift of the activation curve and the reversal poten-
tial of the pacemaker current (If ) to more negative
potentials [9]. In contrast, it has been reported that
the main e¡ect of salicylate is shortening of the ac-
tion potential, which is not a typical antiarrhythmic
action [10]. Therefore, it is not clear whether salic-
ylate alone has an antiarrhythmic e¡ect or not. It
has been demonstrated that salicylate enhances the
blocking action of sodium (Na) channels induced
by procainamide in nerve [11,12]. So, we hypothe-
sized that salicylate in combination with class 1 anti-
arrhythmic agents may exert a more potent inhibi-
tion of the cardiac Na channel, which in turn might
modify the pro- or anti-arrhythmic e¡ects of class 1
antiarrhythmic agents. Therefore, we examined the
e¡ect of salicylate on the depression of the Na cur-
rent induced by class 1 antiarrhythmic agents in ven-
tricular myocytes using the whole cell patch clamp
technique and conventional microelectrode techni-
ques. Moreover, we discuss the mechanism of the
interaction between salicylate and class 1 antiar-
rhythmic agents.
2. Materials and methods
2.1. Multicellular preparation
Guinea pigs weighing 250^300 g were killed by a
blow on the neck. The papillary muscles (5^8 mm
long and 0.8^1.0 mm in diameter) from both ven-
tricles were removed, ¢xed in a tissue bath and super-
fused with normal Tyrode’s solution (mM) (NaCl
137, KCl 5.4, MgCl2 1.0, CaCl2 1.8, NaHCO3 12,
NaH2PO4 0.4, glucose 5.5, pH 7.4) bubbled with
95% O2 and 5% CO2 at a constant £ow rate (3 ml/
min). The temperature was maintained at 36 þ 0.2‡C.
The preparation was stimulated using a ring elec-
trode. Using this ring electrode, an homogeneous
spread of excitation along the preparation is en-
hanced [13]. Only cathodal pulses of constant inten-
sity (1.4^1.6 times threshold strength) were used for
the stimulation, because the anodal pulses of di¡er-
ent intensities sometimes a¡ected the amplitude of
Vmax. The transmembrane potential (Em) was meas-
ured with a conventional glass microelectrode. The
Vmax was obtained using an electronic di¡erentiator
which was linear from 0 to 500 V/s. The signal was
monitored on an oscilloscope and recorded using a
motorized camera.
All procedures met the guidelines stipulated by the
Animal Ethics Committee of Tottori University Fac-
ulty of Medicine.
2.2. Single cell experiments
Single guinea pig ventricular myocytes were iso-
lated using the enzymatic dissociation technique de-
scribed previously [14].
The sodium current (INa) of single ventricular cells
was recorded using the whole cell voltage clamp tech-
nique. The chamber was continuously perfused at a
temperature of 17‡C with a low sodium bathing sol-
ution having the following composition (mM): NaCl
10, CsCl 5, CaCl2 1.8, MgCl2 0.5, CoCl2 1.0, D-glu-
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cose 5.5, HEPES 20, tetramethylammonium chloride
125, and titrated to a pH of 7.4 with 1 mM tetrame-
thylammonium (TMA) hydroxide. The solution in-
side the suction pipette contained (mM): CsF 145,
NaF 10, HEPES 5, and was titrated to a pH of 7.2
with 1 mM CsOH, where £uoride has a su⁄cient
Ca2 bu¡ering e¡ect [15]. Use of this solution al-
lowed an e¡ective isolation of INa from other ionic
currents. The pipette had a tip resistance of less than
0.5 M6. Cell capacitance (Cm) was estimated from
the current transient produced by a small (10 mV)
voltage clamp step, and determined by integrating
the current transient; Cm = 74 þ 6 pF (n = 5). Series
resistance (Rs) was determined by ¢tting the expo-
nential to the current transient which was well de-
scribed by a single exponential. Rs was estimated
from the time constant (t) of the capacitive transient
on the assumption of t = RsCm. Mean time constant
was 98 þ 8 Ws (n = 5), and Rs was 1.3 þ 0.4 M6
(n = 5). The membrane current signal was ¢ltered at
10 kHz with a two-pore active ¢lter, digitized at a
sampling rate of 40 kHz, and recorded on videotapes
(video recorder, Mitsubishi HV-F73, Mitsubishi, To-
kyo, Japan) through a PCM converter (Shoshin EM,
PCM-DP16, Shoshin, Tokyo, Japan) for later com-
puter analysis (NEC PC98XL, NEC, Tokyo, Japan).
Several criteria described by Colatsky and Tsien [16]
that permit indirect determination of the adequacy of
space-clamp control in the cardiac preparation were
used.
1. The inward current record shows a smooth decay,
with no secondary humps or ‘abominable
notches’.
2. The time course of the current remains unchanged
when its magnitude varies due to prepulse inacti-
vation.
3. The measured reversal potential lies close to the
theoretically expected value.
4. The activation is a gradual function of the mem-
brane potential of which the current-voltage curve
has a wide (s 25 mV) negative slope region, ex-
tending over a range of about 50 mV as in other
excitable tissue.
Under our experimental conditions [17^19], cur-
rent recordings from isolated myocytes satis¢ed
these criteria, as shown in the original current
traces of control and the I^V curve of the control
(Fig. 2).
Calcium inward current (ICa) and delayed recti¢er
potassium current (IK) were also measured using the
whole cell patch clamp techniques. For ICa measure-
ment, KCl in the external and pipette solutions was
replaced by CsCl to eliminate the in£uence of potas-
sium currents. The chamber was continuously per-
fused at a temperature of 36‡C with a bathing sol-
ution having the following composition (mM): NaCl
136.9, CsCl 5.4, CaCl2 1.8, MgCl2 0.5, NaH2PO4
0.33, D-glucose 5, HEPES 5, and titrated to a pH
of 7.4 with 1 M NaOH. The solution inside the suc-
tion pipette contained (mM): CsCl 120, NaH2PO4
10, EGTA 1, MgATP 5, HEPES 10, and was titrated
to a pH of 7.2 with 1 mM CsOH.
In experiments to measure IK, the normal Tyrode’s
external solution was replaced by a sodium-free and
potassium-free solution including nisoldipine in or-
der to isolate the current from other current compo-
nents. The composition of the solution was as fol-
lows (mM): N-methylglutamine 149, MgCl2 5, CaCl2
1.8, HEPES 5, nisoldipine 0.0003. Various depolari-
zation steps up to +50 mV with a duration of 3 s
were applied at a frequency of 0.03 Hz from the
holding potential at 340 mV.
2.3. De¢nition of tonic and phasic block of either INa
or Vmax induced by antiarrhythmic agents
It is known that the block induced by antiarrhyth-
mic agents of either Vmax of the action potential in
the papillary muscle or INa in a single ventricular cell
is composed of a tonic block and a phasic block.
To study the block of either INa or Vmax under
steady-state conditions (tonic block), the decrease
in either INa or Vmax during exposure to the drug
was de¢ned as tonic block [17,20] at low pulse fre-
quency of stimuli (0.1 Hz) which is su⁄cient to en-
sure full recovery from the use-dependent block of
either Vmax or INa. The extent of the tonic block was
calculated as the percent decrease in both Vmax and
INa after perfusion with the drug with respect to the
control.
To study the use-dependent block (phasic block)
of either INa or Vmax, the decrease of either Vmax or
INa during a pulse train following a rest of 180 s was
de¢ned as the phasic block. The extent of the phasic
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block was calculated as the percent decrease in either
Vmax or INa in the new steady state (20th pulse) with
respect to that of the ¢rst pulse [17,20].
2.4. Drugs
The following drugs were used: salicylate-sodium
(Nakarai Chemical, Tokyo, Japan), quinidine (Na-
karai Chemical), aprindine (Mitsui Pharmaceutical,
Tokyo, Japan), disopyramide (Chugai Pharmaceuti-
cal, Tokyo, Japan), mexiletine (Boehringer Inger-
heim, Germany) and procainamide (Daiichi Pharma-
ceutical, Tokyo, Japan).
Even at the highest concentration used in the study
(3 mM) salicylate did not change the pH of the sol-
ution (pH = 7.35 þ 0.05 in control, 7.35 þ 0.07 in the
presence of salicylate at 1 mM, 7.34 þ 0.02 in the
presence of salicylate at 3 mM, respectively; n = 4).
2.5. Data analysis
Analysis of the data was performed on a computer
(Macintosh LC630) using custom software. All curve
¢tting was done with a non-linear least squares algo-
rithm using a Marquardt routine. The results were
expressed as the mean (S.E.M.). Statistical analysis
was done using the one-way repeated measures (AN-
OVA) test, and the results were considered to be
signi¢cant when the P value was less than 0.05.
3. Results
3.1. E¡ects of salicylate on the parameters of the
action potential of the ventricular muscle and on
the membrane ionic currents of a ventricular
myocyte
Table 1 summarizes the values of the various pa-
rameters of membrane action potential of guinea pig
papillary muscle constantly driven at 0.1 Hz, after
exposure to di¡erent concentrations of salicylate.
Electrophysiological measurements were made before
(control) and 30 min after exposure to the test sol-
Table 1
E¡ects of salicylate on the parameters of the action potential of the ventricular muscles and on the membrane ionic currents of a ven-
tricular myocytes
Vmax (V/S) RP (mV) APA (mV) APD90 (mV)
Control 257 þ 21 383 þ 1 123 þ 4 235 þ 33
Salicylate (mM)
0.03 257 þ 24 383 þ 1 121 þ 5 223 þ 37
0.1 257 þ 24 383 þ 1 121 þ 5 223 þ 41
0.3 261 þ 28 383 þ 1 121 þ 6 200 þ 53*
1.0 257 þ 23 383 þ 2 115 þ 3* 118 þ 18**
3.0 236 þ 15 378 þ 4* 106 þ 9** 55 þ 15**
Quinidine 10 WM 233 þ 24* 383 þ 3 123 þ 2 272 þ 10**
Quinidine 10 WM+salicylate (mM)
0.03 211 þ 25* 383 þ 3 123 þ 2 265 þ 30
0.1 197 þ 16* 383 þ 1 122 þ 3 266 þ 27
0.3 173 þ 15** 383 þ 2 113 þ 3* 174 þ 40**
1.0 164 þ 15** 381 þ 6 103 þ 2** 96 þ 14**
3.0 128 þ 24** 378 þ 2** 93 þ 4** 54 þ 14**
Salicylate (mM) INa (%) (HP =3100 mV) INa (%) (HP =3140 mV) ICa (%) IK (%)
0.3 0 (n = 4) 0 (n = 4) 12.5 þ 7.6 (n = 5) 29 þ 0.4 (n = 4)
1.0 0 (n = 4) 0 (n = 4) 22.6 þ 6.8 (n = 5) 42 þ 5.6 (n = 4)
The upper part of the table indicates the e¡ects of salicylate on the parameters measured after exposure to di¡erent concentrations of
salicylate (n = 5). The middle part indicates the e¡ects of salicylate on the parameters measured after exposure to di¡erent concentra-
tions of salicylate in the presence of quinidine (n = 5). The lower part indicates the INa, ICa, and IK of a ventricular cardiac myocyte
after exposure to salicylate (0.3 and 1 mM).
Vmax, maximum rate of rise; RP, resting potential ; APA, action potential amplitude; APD90, action potential at 90% repolarization.
*P6 0.05, **P6 0.01, compared with control values.
BBAMEM 77598 3-5-99
Y. Tanaka et al. / Biochimica et Biophysica Acta 1418 (1999) 320^334 323
ution containing the various concentrations of salic-
ylate (0.03^3 mM). Although salicylate at 3 mM did
not signi¢cantly a¡ect the Vmax, the resting mem-
brane potential (RP) signi¢cantly depolarized at the
highest concentration of salicylate. Salicylate signi¢-
cantly reduced both the action potential amplitude
(APA) and the action potential duration at 90% re-
polarization (APD90) in a dose-dependent manner.
We also studied the action potential parameters in
the presence of both quinidine at 10 WM and of dif-
ferent concentrations of salicylate. Quinidine alone
signi¢cantly prolonged APD90 (P6 0.01) and re-
duced Vmax (P6 0.05) without changes in APA and
RP. RP signi¢cantly depolarized at the highest con-
centration of salicylate even in the presence of quini-
dine. Salicylate signi¢cantly reduced both APA and
APD90 in a dose-dependent manner, even in the pres-
ence of quinidine. Interestingly, salicylate enhanced
the block of Vmax induced by quinidine in a dose-
dependent manner. These results suggested that sa-
licylate alone might change the membrane currents
responsible for the plateau phase of the action po-
tential (APD90); and salicylate might enhance the
block of INa induced by quinidine, although salicy-
late alone did not a¡ect the INa. To con¢rm these
¢ndings we studied the e¡ects of salicylate alone on
INa, ICa and IK of individual cardiomyocytes using
the whole cell patch clamp techniques. As shown in
Table 1, salicylate at 1 mM did not a¡ect INa elicited
by a test potential of 30 ms to 320 mV either at an
HP of 3100 mV or of 3140 mV, although salicylate
signi¢cantly blocked ICa as well as IK in a dose-de-
pendent manner (P6 0.01). These results suggested
that salicylate would shorten the action potential du-
ration by reducing ICa but would not a¡ect INa.
3.2. Enhancing e¡ect of salicylate on the tonic block
of INa induced by quinidine in single cardiac cells
Quinidine at 30 WM decreased INa by 58% (from
1.3 to 0.54 nA) elicited by a test potential of 30 ms to
330 mV at an HP of 3100 mV (Fig. 1a,b) at 0.1 Hz.
Addition of 1 mM salicylate to the quinidine-con-
taining medium resulted in a further decrease of
INa from 0.54 to 0.18 nA (367%; Fig. 1b,c). After
a 15 min washout of quinidine and salicylate, this
enhancing e¡ect of salicylate disappeared and the
amplitude of INa returned to the same level as before
Fig. 1. Enhancing e¡ects of salicylate on the tonic block of INa induced by quinidine at di¡erent holding potentials. (a,e) INa elicited
by the test potential to 330 mV at 0.1 Hz from either an HP =3100 mV or 3140 mV. (b,f) E¡ects of quinidine at 30 WM on INa at
either an HP =3100 mV or 3140 mV. (c,g) E¡ect of salicylate at 1 mM on INa at either an HP =3100 mV or 3140 mV in the pres-
ence of quinidine at 30 WM. (d,h) E¡ect of salicylate washout on INa. Note that salicylate enhanced the tonic block of INa induced by
quinidine at an HP =3100 mV but not at an HP =3140 mV. The vertical bar indicates 1 nA and the horizontal one 10 ms.
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the addition of salicylate (Fig. 1d). At an HP of
3140 mV, 30 WM quinidine reduced INa from 1.4
to 0.93 nA (Fig. 1e,f). However, addition of 1 mM
salicylate to the quinidine-containing medium did
not result in a further reduction of INa which on
the contrary increased to 1.1 nA (Fig. 1g). After
the washout of both quinidine and salicylate, the
amplitude of INa returned to the same level as before
the addition of salicylate (Fig. 1h).
To avoid the possibility that salicylate shifted the
gating kinetics during the experiment, the current^
voltage relationship of the Na current was re-
corded. The INa under control, in the presence of
30 WM quinidine, in the presence of 30 WM quini-
dine+1 mM salicylate and after washout of both
quinidine and salicylate is shown in Fig. 2. INa was
elicited by 5 mV step depolarizing pulses from an HP
of 3100 mV at 0.1 Hz. In comparison with the am-
plitude of INa under control conditions (a: peak
INa = 3 nA), quinidine at 30 WM produced the tonic
block of INa (b: 342% peak INa = 1.74 nA).
The addition of 1 mM salicylate to the quinidine-
Fig. 2. E¡ects of quinidine on the current-voltage relationship of Na current in the absence and presence of salicylate. (a^d) The
original current traces of Na current under control conditions, in the presence of quinidine (30 WM), in that of quinidine+salicylate
(1 mM), and during washout. The holding potential was kept at 3100 mV and depolarized by 5 mV step depolarizing pulses of 30
ms duration at 0.1 Hz. (e) The I-V curve of Na current under control conditions (E), in the presence of 30 WM quinidine (8), in
that of quinidine+1 mM salicylate (F), and during washout (R). Note that salicylate could enhance the tonic block of INa induced by
quinidine without changes in either threshold, peak or equilibrium potential.
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containing medium enhanced the tonic block by 67%
(c: peak INa = 0.99 nA). After 15 min washout of
quinidine and salicylate, this enhancing e¡ect of sa-
licylate was abolished and the amplitude of INa re-
turned to the same level as before adding salicylate
(d: peak INa = 1.75 nA). As shown in the I^V curve,
there was no shift of either the threshold (360 mV),
peak (335 mV), or equilibrium potential of INa (0
mV) under control conditions, in the presence of 30
WM quinidine alone, in the presence of quinidine+1
mM salicylate, or during washout of both quinidine
and salicylate.
Fig. 3 shows the Hill plots of the concentration-
dependent tonic block of INa by quinidine (3^60 WM)
in the presence and absence of 1 mM salicylate at an
HP of 3100 mV and of 3140 mV. Each point rep-
resents the mean (S.E.M.) of ¢ve experiments.
We calculated the Kd;app and Hill coe⁄cient using
the following equation:
% change  1=1 Dn=Kd;app 1
where D means dose of quinidine, n means Hill co-
e⁄cient, and Kd;app means the dose for 50% block.
At an HP of 3100 mV, 1 mM salicylate signi¢-
cantly enhanced the tonic block of INa by quinidine
at various quinidine concentrations, so that the re-
sponse to quinidine in the presence of 1 mM salicy-
late (Kd;app = 11.8 WM; P6 0.05) was shifted to a
substantially lower concentration of quinidine
(Kd;app = 22.8 WM) without changes in Hill coe⁄cient
( = 1.0) as shown in Fig. 3A. In contrast, at an HP of
3140 mV salicylate did not cause a shift of the re-
Fig. 3. Hill plot of the concentration-dependent tonic block of INa induced by quinidine at either an HP =3100 mV or 3140 mV.
The ordinate shows (% tonic block of INa)/(100%3% tonic block of INa), and the abscissa indicates the log of salicylate concentration
(3^60 WM). (A) Hill plot of the tonic block of INa induced by quinidine at an HP =3100 mV. E, quinidine alone; F, quinidine in the
presence of 1 mM salicylate. *P6 0.05. (B) Hill plot of the tonic block of INa induced by quinidine at an HP =3140 mV. O, quini-
dine alone; R, quinidine in the presence of 1 mM salicylate. Note that salicylate could shift the dose response of quinidine to the left
side at an HP =3100 mV but not at an HP =3140 mV. Each point represents the mean value of ¢ve experiments.
Fig. 4. E¡ect of salicylate on the hr curve in the presence of
quinidine. b, control conditions; 8, 10 WM quinidine; F, 10
WM quinidine plus 1 mM salicylate to the quinidine-containing
medium; O, during washout. The ordinate shows the availabil-
ity of the Na channels and the abscissa the prepulse poten-
tials. Note that salicylate shifted the hr curve in the presence
of quinidine further in the hyperpolarized direction.
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sponse to quinidine (Kd;app = 30 WM) as shown in Fig.
3B.
Fig. 4 shows the steady-state inactivation curve of
INa under control conditions, in the presence of 10
WM quinidine and in the presence of both 10 WM
quinidine and 1 mM salicylate. The inactivation
curve of INa was assessed at selected membrane (pre-
pulse) potential using a standard two-pulse protocol
from an HP of 3140 mV. A 1 s prepulse to the
designated level of membrane potential was followed
by a 0.5 ms interpulse interval then by a 30 ms test
pulse of 320 mV. The protocol sequence was applied
once every 40 s. The curve drawn through the data
points is described by the following equation:
hr  1 expVm3Vh=k31 2
where Vm is the prepulse potential, Vh is the prepulse
potential at h = 0.5 and k is a slope factor. Under
control conditions, Vh was 381.8 mV and k was
8.6, while in the presence of 10 WM quinidine, Vh
was 385.3 mV and the slope factor was 8.6, and in
the presence of both 10 WM quinidine and 1 mM
salicylate, Vh was 391.0 mV and the slope factor
was 8.7. After the washout, Vh was 386.0 mV and
the slope factor was 8.8. From the data obtained
from four experiments, 10 WM quinidine signi¢cantly
shifted the INa inactivation curve by 33.2 þ 1.7 mV
(P6 0.05) and treatment with both 10 WM quinidine
and 1 mM salicylate further produced a signi¢cant
shift of INa inactivation by 39.9 þ 3.4 mV (P6 0.05)
in the hyperpolarized direction along the voltage axis
while the slope factor remained unchanged at
8.6 þ 2.2.
3.3. Enhancing e¡ect of salicylate on the phasic block
of INa induced by quinidine in single cardiac cells
Fig. 5a^d shows the enhancing e¡ect of salicylate
Fig. 5. E¡ect of salicylate on the phasic block of INa induced by quinidine at di¡erent holding potentials. a, INa elicited by the ¢rst
depolarizing pulse to 320 mV; b, INa elicited by the 20th pulse at either an HP =3100 mV or 3140 mV. (a,c) In the presence of 30
WM quinidine; (b,d) in the presence of both 30 WM quinidine and 1 mM salicylate. (Lower panels) Phasic block of INa at either an
HP =3100 mV (left panel : n = 4) or HP =3140 mV (right panel: n = 4). Qui, in the presence of 30 WM quinidine; Qui+Sal, in the
presence of both 30 WM quinidine and 1 mM salicylate. *P6 0.05. Note that salicylate enhanced the phasic block of INa induced by
quinidine at an HP =3100 mV but not at an HP =3140 mV.
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on the quinidine-induced phasic block of INa elicited
by the ¢rst 30 ms depolarizing pulse (open circle) at
2 Hz from either an HP of 3100 mV or an HP of
3140 mV to 320 mV and by the 20th pulse (closed
circle) in the absence or presence of 1 mM salicylate.
At an HP of 3100 mV, 30 WM quinidine produced a
phasic block (to 58%, Fig. 5a). The addition of 1 mM
salicylate enhanced the phasic block of INa induced
by 30 WM quinidine by 85% (Fig. 5b). In contrast, at
an HP of 3140 mV, 30 WM quinidine produced a
phasic block of INa (28%, Fig. 5c), but the addition
of 1 mM salicylate did not enhance the phasic block
of INa induced by quinidine (23%, Fig. 5d). The
lower panels of Fig. 5 show the summary of the
Fig. 6. Concentration-dependent enhancing e¡ects of salicylate on the tonic block of Vmax by class 1 antiarrhythmic drugs. The ordi-
nate indicates the % tonic block of Vmax and the abscissa the salicylate concentration. (A) In the presence of 10 WM quinidine; (B) in
the presence of 1 WM aprindine; (C) in the presence of 20 WM disopyramide; (D) in the presence of 100 WM procainamide; (E) in the
presence of 50 WM mexiletine. Note that salicylate signi¢cantly enhanced the tonic block of Vmax induced by aprindine or disopyr-
amide but not that induced by procainamide or mexiletine. Each point represents the mean value of ¢ve experiments. *P6 0.05,
**P6 0.01.
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enhancing e¡ects of salicylate on the phasic block
obtained from each of the four experiments. At an
HP of 3100 mV, 1 mM salicylate could signi¢cantly
enhance the phasic block induced by 30 WM quini-
dine (54 þ 12% without salicylate vs. 87 þ 15% with
1 mM salicylate; P6 0.05). On the contrary, at an
HP of 3140 mV 1 mM salicylate did not enhance the
phasic block of INa induced by 30 WM quinidine
(28 þ 19% without salicylate vs. 24 þ 14% with 1 mM
salicylate).
3.4. Modi¢cation of the tonic and phasic block of
Vmax of the action potential induced by the class 1
antiarrhythmic drugs by salicylate
Since salicylate speci¢cally enhanced the tonic and
phasic blocks of INa induced by quinidine at a par-
tially depolarized membrane potential (at an HP of
3100 mV) but not at a well-polarized membrane
potential (at an HP of 3140 mV), we thought that
salicylate might enhance the tonic and phasic block
Fig. 7. Concentration-dependent e¡ects of salicylate on the phasic block of Vmax induced by class 1 antiarrhythmic drugs. The ordi-
nate indicates the % phasic block of Vmax and the abscissa the interstimulus interval. (A) In the presence of 10 WM quinidine; (B) in
the presence of 1 WM aprindine; (C) in the presence of 20 WM disopyramide; (D) in the presence of 100 WM procainamide; (E) in the
presence of 50 WM mexiletine. a, class 1 antiarrhythmic drug alone; F, class 1 antiarrhythmic drug combined with 0.1 mM salicylate;
E, class 1 antiarrhythmic drug combined with 1 mM salicylate. Note that salicylate signi¢cantly enhanced the phasic block of Vmax in-
duced by aprindine or disopyramide but not that induced by procainamide or mexiletine. Each point represents the mean value of
¢ve experiments. *P6 0.05.
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of Vmax of the action potential at the resting mem-
brane potential (RP = around 380 mV) induced by
class 1 antiarrhythmic agents. Fig. 6 shows the e¡ects
of salicylate on the tonic block of Vmax induced by
quinidine, aprindine, disopyramide, procainamide
and mexiletine in each of the ¢ve experiments. Salic-
ylate signi¢cantly enhanced the tonic block of Vmax
induced by 10 WM quinidine (Fig. 6A), 1 WM aprin-
dine (Fig. 6B), or by 20 WM disopyramide (Fig. 6C)
in a dose-dependent manner (0.1^1 mM). However,
even at the highest concentration of 1 mM, salicylate
failed to enhance the tonic block of Vmax induced by
100 WM procainamide (Fig. 6D) or 50 WM mexiletine
(Fig. 6E).
Fig. 7 shows the e¡ects of salicylate on the phasic
block of Vmax induced by quinidine, aprindine, dis-
opyramide, procainamide and mexiletine in each of
the ¢ve experiments. Salicylate signi¢cantly enhanced
the tonic block of Vmax induced by 10 WM quinidine
(Fig. 7A), 1 WM aprindine (Fig. 7B), or 20 WM dis-
opyramide (Fig. 7C) in a dose-dependent manner
(0.1^1 mM). However, even at the highest concen-
tration of 1 mM, salicylate failed to enhance the
tonic block of Vmax induced by 100 WM procain-
amide (Fig. 7D) or 50 WM mexiletine (Fig. 7E).
4. Discussion
4.1. Mechanism of the enhancing e¡ects of salicylate
based on the modulated receptor hypothesis
From the single cell experiments, we concluded
that salicylate enhanced the quinidine-induced tonic
block and phasic block of Na channels at a de-
polarized membrane potential but not at a hyper-
polarized membrane potential, enhancing the hyper-
polarizing shift in the hr curve induced by quini-
dine.
According to the modulated receptor theory [21],
(1) drugs bind to a receptor site on or very close to
the sodium channel, (2) the a⁄nity of the receptor
for the drug is modulated by the channel state: the
resting, the inactivated, and the activated state, (3)
drug-associated channels di¡er from drug-free chan-
nels in that they do not conduct, and their ability to
be activated is shifted to a more negative potential. It
is well known that under steady-state conditions the
tonic block is composed of the resting state block
and the inactivated state block [21].
Scheme 1 is a simpli¢ed scheme showing the rela-
tionship between the quinidine molecule and both
the resting and inactivated states of the channel. In
this scheme D is the drug molecule, R is the resting
state, RD is the resting state with the neutral form of
drug bound, I is the inactivated state, and ID is the
inactivated state with the neutral form of the drug
bound. kr and ki are the drug-binding rate constants.
lr and li are the corresponding dissociation rate con-
stants. K is the forward rate constant from I to R
(Kc) or from ID to RD (Kd). L is the backward rate
constant from R to I (Lc) or from RD to ID (Ld).
KdR and KdI are the equilibrium dissociation con-
stants for the resting and inactivated states, respec-
tively (KdR = lr/kr, KdI = li/ki). Based on the modu-
lated receptor hypothesis, administration of salic-
ylate could further reduce the quinidine-induced re-
duction of the number of available channels under
steady-state conditions. There are two possible ex-
planations regarding the salicylate-induced reduction
of the available channels in the presence of quinidine.
1. Salicylate could increase the number of drug-
bound non-conducting channels by decreasing
the KdI.
2. Salicylate could increase the number of drug-
bound inactivated channels (ID) through the ac-
celeration of the transition from RD to ID by
shifting the hr curve toward the hyperpolarized
direction.
To examine the above possibilities, we applied the
Scheme 1.
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experimental values of KdR, slope factor, and Vh to
the equations below and calculated the probability of
Na channels dwelling in R (drug-free resting state)
in the presence of 10 WM quinidine before and after
adding the 1 mM salicylate according to the Erying
rate theory. We assumed that Na channels transited
between R (RD) and I (ID) over the energy barrier
as shown in Scheme 2.
In this scheme K and L represent the rate constants
for the state transitions, vGR, vGI and vGRI de-
note the energy di¡erence in the Gibbs free energy
among state (in RT unit). The forward and backward
rate constants were expressed as functions of energy
di¡erences.
K  kT=hfexp3vGI  DzFV=RT g 3
L  kT=fexp3vGR  D31zFV=RT g 4
vGI  vGR  vGRI 5
vGRI  3Vh=S 6
S  RT=zF 7
where S is the slope factor, z the number of gating
charges, N the electrical distance and Vh the midpoint
potential of the hr curve. h, k, R, F and T have their
usual meanings.
A drug could bind to or dissociate from the recep-
tor over the energy barrier as shown in Scheme 3.
In this scheme k and l are the rate constants for
drug-binding and drug dissociation, and vGk, vGkl,
and vGl are the energy di¡erences among the states.
Association and dissociation rate constants are given
by the following equations:
k  kT=hfexp3vGkg 8
l  kT=hfexp3vGlg 9
vGl  vGk  vGkl 10
vGkl  lnKd  lnl=k 11
Since the experimental data obtained by Koumi et
al. [22] showed that the recovery time constant of
quinidine from the resting state block was 8.4 þ 1.9
s, we assumed that the rate of transition between R
and RD was similar to that of the transition between
I and ID. Using the equations described above, we
calculated the probability of state R (hr curve) in the
presence of 10 WM quinidine before and after adding
1 mM salicylate. As illustrated in Fig. 8A,B, the re-
duction of the KdI value resulted in a shift of the
midpoint of the hr curve to the hyperpolarized di-
rection and was accompanied by a reduction of the
Kd;app values.
Under a KdI of 9.8 WM and a KdR of 30 WM (as
depicted by KdI = 9.8 in Fig. 8C,D) the Vh was 389.1
mV, S was 8.6 and Kd;app was 22.7 WM, which was
very close to the experimental data obtained in the
presence of 10 WM quinidine only. Under a KdI of 2.8
WM and a KdR of 30 WM (as depicted by KdI = 2.8 in
Fig. 8C,D) the Vh was 396.1 mV, S was 8.6 and
Kd;app was 11.9 WM, which was very close to the
experimental data obtained in the presence of 10
WM quinidine+1 mM salicylate.
Therefore we concluded that salicylate enhanced
the quinidine-induced tonic block of Na channels
Scheme 2.
Scheme 3.
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by decreasing the KdI for quinidine from 9.8 WM to
2.8 WM without changing the KdR (30 WM) for qui-
nidine, and resulting in the reduction of Kd;app for
quinidine. In other words, salicylate could increase
the number of drug-bound non-conducting state Na
channels through the acceleration of the transition
from I to ID by increasing the a⁄nity of quinidine
to the inactivated state channel.
This would explain the enhancement of the quini-
dine-induced phasic block of Na channels by salic-
ylate as well. As phasic block is composed of the
activated and/or the inactivated state block, the sa-
licylate-induced increase in the a⁄nity of quinidine
to the inactivated state channels would lead to an
accumulation of the quinidine-bound non-conduct-
ing inactivated channels during the train of stimuli,
resulting in an increased phasic block of quinidine.
4.2. Mechanisms of the enhancing e¡ects of salicylate
based on the structure of class 1 antiarrhythmic
agents
The fact that salicylate enhanced quinidine-, aprin-
dine-, and disopyramide-induced tonic and phasic
blocks of Vmax, but not procainamide- or mexile-
tine-induced tonic and phasic blocks is very interest-
ing. These di¡erences could be related either to their
action potential prolonging e¡ect [23,24] or to their
chemical structure.
In the present study, salicylate always shortened
the action potential duration mainly via inhibition
of Ca channels even in the presence of quinidine
(as shown in Table 1) as well as in that of the other
class 1 antiarrhythmic agents (data not shown).
Therefore, changes in the action potential duration
Fig. 8. Prediction of the voltage-dependent availability curve of INa or concentration dependence of quinidine block of INa in the pres-
ence and absence of salicylate. (A,B) Dependence of Vh (A) and Kd;app (B) on KdI. Steady-state probability of state R in Scheme 1
was calculated from Eqs. 2^10 to construct the voltage-dependent availability curve or concentration dependence of quinidine block,
and then the Vh or Kd;app was determined by a ¢t with Eq. 1. KdI = 1, 2, 3, 4, 5, 10, 20, 30, 40, 50 WM. vGlc =vGlb = 32RT,
vGlr =vGli = 32RT. (C,D) Voltage-dependent availability (C) and concentration dependence of quinidine block (D) in the absence
(KdI = 9.8 WM) or presence (KdI = 2.8 WM) of salicylate. The steady-state probabilities of state R were normalized to the maximum val-
ues determined by the ¢ts with Eq. 1. The numbers in the ¢gure represent the mid-potentials in mV (C) or the IC50 values in WM
(D).
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would not explain the heterogeneity of the enhancing
e¡ect of salicylate on the phasic block of Vmax in-
duced by class 1 antiarrhythmic agents.
The receptor site for local anesthetics in nerve Na
channels has been suggested to lie within the channel
lumen [25], and a drug would thus reach it from the
pore or through the lipid bilayer of the cell mem-
brane, i.e., the former is the hydrophilic pathway
and the latter is the hydrophobic pathway. The hy-
drophilic pathway is only used by the charged form
of the drug, which is favored by a low molecular
weight, while the hydrophobic pathway is only used
by the neutral form of the drug, which is favored by
its lipid solubility estimated by log P (log of the n-
octanol:water partition coe⁄cient) [26^29]. Although
the ratio of neutral to charged form of each drug is
known to depend on its pKa, quinidine, aprindine,
disopyramide, procainamide, and mexiletine have al-
most the same pKa values, that is, 8.6^9.2. Therefore,
there is no di¡erence in the proportion of the neutral
forms among these antiarrhythmic agents. As the
values of log P of quinidine (3.6), aprindine (5.0)
and disopyramide (1.8) are higher than those of pro-
cainamide (0.8) and mexiletine (1.3) [30], quinidine,
aprindine and disopyramide have stronger lipophilic-
ity than procainamide and mexiletine. Consequently,
salicylate might speci¢cally enhance the blocking ef-
fect of a drug which mainly uses the hydrophobic
pathway. It has been reported in nerve that organic
acid salts like salicylate or butyrate enhanced the
action of local anesthetics, and this was attributed
to an acceleration of the adsorption of the local anes-
thetics to the lipid bilayer and a decreased adsorption
ratio without changes in the desorption rate [12].
This information would support the hypothesis that
salicylate increased the intracellular concentration of
the drug by accelerating the absorption of drugs with
stronger lipid solubility to the lipid bilayer, resulting
in an enhancement of the tonic and phasic blocks of
Vmax induced by class 1 antiarrhythmic agents.
4.3. Limitations and clinical relevance of the study
Since class 1 antiarrhythmic agents were utilized in
the present experiment at concentrations slightly
higher than the therapeutic range for patients with
arrhythmia (quinidine 6 9 WM, aprindine 6 6.7 WM,
disopyramide 6 17.7 WM, procainamide 6 73.6 WM,
and mexiletine 6 9.3 WM) and higher than the dose
commonly prescribed for post-myocardial infarction
patients, the clinical relevance of the present work is
limited. The dose of salicylate used here was far in
excess of the e¡ective levels in cardiac patients as
well, although the therapeutic plasma concentration
of salicylate for rheumatic disease is approx. 0.625^
1.87 mM [31] and these concentrations are large
enough to attain the enhancing e¡ect of salicylate
on the class 1 antiarrhythmic agent-induced block
of Vmax. However, the salicylate-induced enhancing
e¡ects on the blocking action of the class 1 antiar-
rhythmic agents with high lipid solubility could pro-
duce a new area of unidirectional block in the depo-
larized (diseased) cardiac cells.
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